Therefore, differences in CTSL levels could offer a therapeutic window allowing QC to preferentially target ovarian cancer cells—especially those that have developed chemoresistance—while maintaining minimal overall toxicity in vivo. This evidence concerns the gene CTSL and ovarian cancer.